News
Medical Device Network on MSN11h
Novocure’s device for metastatic NSCLC treatment gains CE MarkThe data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback